A double-blind study of heteronium bromide and amobarbital in the management of gastrointestinal conditions associated with anxiety.
D000328:Adult; D000368:Aged; D000654:Amobarbital / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003109:Colonic Diseases, Functional / Q000188:drug therapy*; D004381:Duodenal Ulcer / Q000188:drug therapy*; D005260:Female; D005769:Gastrointestinal Motility / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D010437:Peptic Ulcer / Q000188:drug therapy*; D010634:Phenobarbital / Q000627:therapeutic use; D010919:Placebos; D011413:Propantheline / Q000627:therapeutic use; D011602:Psychophysiologic Disorders / Q000188:drug therapy; D011759:Pyrrolidines / Q000627:therapeutic use*; D013876:Thiophenes / Q000627:therapeutic use
D010919:Placebos; D011759:Pyrrolidines; D013876:Thiophenes; D011413:Propantheline; D000654:Amobarbital; D010634:Phenobarbital